Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Activating mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), in particular, a point mutation leading to a glycine-to-cysteine substitution at codon 12 (G12C), are among the most frequent genomic alterations in non-small cell lung cancer (NSCLC). Several agents targeting KRAS G12C have recently entered clinical development. Sotorasib, a first-in-class specific small molecule that irreversibly inhibits KRAS G12C, has since obtained Health Canada approval. The emergence of novel KRAS-targeted therapies warrants the development of evidence-based consensus recommendations to help clinicians better understand and contextualize the available data. A Canadian expert panel was convened to define the key clinical questions, review recent evidence, and discuss and agree on recommendations for the treatment of advanced KRAS G12C-mutated NSCLC. The panel agreed that testing for KRAS G12C should be performed as part of a comprehensive panel that includes current standard-of-care biomarkers. Sotorasib, the only approved KRAS G12C inhibitor in Canada, is recommended for patients with advanced KRAS G12C-mutated NSCLC who progressed on guideline-recommended first-line standard of care for advanced NSCLC without driver alterations (immune-checkpoint inhibitor(s) [ICIs] +/− chemotherapy). Sotorasib could also be offered as second-line therapy to patients who progressed on ICI monotherapy that are not candidates for a platinum doublet and those that received first-line chemotherapy with a contraindication to ICIs. Preliminary data indicate the activity of KRAS G12C inhibitors in brain metastases; however, the evidence is insufficient to make specific recommendations. Regular liver function monitoring is recommended when patients are prescribed KRAS G12C inhibitors due to risk of hepatotoxicity.

[1]  C. Dooms,et al.  Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS G12C mutation: a randomised, open-label, phase 3 trial , 2023, The Lancet.

[2]  Marta M. Jankowska,et al.  Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk , 2022, Journal of Cancer Research and Clinical Oncology.

[3]  T. Burns,et al.  OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC , 2022, Journal of Thoracic Oncology.

[4]  G. Jerusalem,et al.  OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation , 2022, Journal of Thoracic Oncology.

[5]  G. Yancopoulos,et al.  Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial , 2022, Nature Medicine.

[6]  M. Frattini,et al.  Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers , 2022, Cancers.

[7]  D. Hong,et al.  Targeting KRAS: Crossroads of Signaling and Immune Inhibition , 2022, Journal of immunotherapy and precision oncology.

[8]  H. Purkey Abstract ND11: Discovery of GDC-6036, a clinical stage treatment for KRAS G12C-positive cancers , 2022, Cancer Research.

[9]  C. Dooms,et al.  Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors , 2022, Cancer Research.

[10]  P. Jänne,et al.  Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. , 2022, The New England journal of medicine.

[11]  S. Ramalingam,et al.  Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100. , 2022, Journal of Clinical Oncology.

[12]  R. Pazdur,et al.  Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. , 2022, Journal of Clinical Oncology.

[13]  C. Mascaux,et al.  37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer , 2022, Annals of Oncology.

[14]  E. Schuuring,et al.  Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study. , 2022, Lung cancer.

[15]  P. Brest,et al.  Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner , 2022, Cancers.

[16]  C. Mascaux,et al.  Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance , 2022, Cancers.

[17]  S. Snow,et al.  Not All Canadian Cancer Patients Are Equal—Disparities in Public Cancer Drug Funding across Canada , 2022, Current oncology.

[18]  P. Garrido,et al.  Targeting KRAS in Non-Small Cell Lung Cancer , 2022, Frontiers in Oncology.

[19]  A. Cardona,et al.  Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer , 2021, Frontiers in Oncology.

[20]  Liang Liu,et al.  Resistance looms for KRAS G12C inhibitors and rational tackling strategies. , 2021, Pharmacology & therapeutics.

[21]  P. Mrigpuri,et al.  Untangling the KRAS mutated lung cancer subsets and its therapeutic implications , 2021, Molecular Biomedicine.

[22]  D. Erdmann,et al.  Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models , 2021, Poster Presentations - Proffered Abstracts.

[23]  M. Berger,et al.  Diverse alterations associated with resistance to KRAS(G12C) inhibition , 2021, Nature.

[24]  S. Digumarthy,et al.  Diminished efficacy of PD-(L)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is impacted by KRAS mutation status. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  R. Govindan,et al.  P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100 , 2021, Journal of Thoracic Oncology.

[26]  V. Aran,et al.  Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients , 2021, Medicina.

[27]  G. Barnett,et al.  Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases , 2021, Scientific Reports.

[28]  F. Gelsomino,et al.  STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive? , 2021, European journal of cancer.

[29]  R. Goldin,et al.  Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report , 2021, JTO clinical and research reports.

[30]  P. Jänne,et al.  Acquired Resistance to KRASG12C Inhibition in Cancer. , 2021, The New England journal of medicine.

[31]  R. Govindan,et al.  Sotorasib for Lung Cancers with KRAS p.G12C Mutation. , 2021, The New England journal of medicine.

[32]  T. Mok,et al.  KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation. , 2021 .

[33]  R. Reis,et al.  Frequency of KRAS p.Gly12Cys Mutation in Brazilian Patients With Lung Cancer , 2021, JCO global oncology.

[34]  Xihong Lin,et al.  Association between Smoking History and Tumor Mutation Burden in Advanced Non–Small Cell Lung Cancer , 2021, Cancer Research.

[35]  F. Hirsch,et al.  KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing. , 2021, The Journal of molecular diagnostics : JMD.

[36]  R. Salgia,et al.  The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) , 2021, Cell reports. Medicine.

[37]  D. Carbone,et al.  First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[38]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[39]  F. Blackhall,et al.  Mechanisms of Resistance to KRASG12C Inhibitors , 2021, Cancers.

[40]  Diane D. Liu,et al.  STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition , 2020, Clinical Cancer Research.

[41]  Li Zhang,et al.  Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer , 2020, Thoracic cancer.

[42]  S. Banerji,et al.  Consensus recommendations for optimizing biomarker testing to identify and treat advanced EGFR-mutated non-small-cell lung cancer. , 2020, Current oncology.

[43]  G. Giaccone,et al.  Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. , 2020, The New England journal of medicine.

[44]  G. Fontanini,et al.  Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review , 2020, Diagnostics.

[45]  Andreas Wicki,et al.  Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms , 2020, Laboratory Investigation.

[46]  F. McCormick,et al.  RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.

[47]  Haiquan Chen,et al.  The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features. , 2020, The Journal of thoracic and cardiovascular surgery.

[48]  F. Meric-Bernstam,et al.  Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns. , 2020 .

[49]  Hong Yu,et al.  Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications. , 2020, Biomedical reports.

[50]  Y. Kluger,et al.  Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. , 2020, The Lancet. Oncology.

[51]  A. Drilon,et al.  KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures. , 2020, Cancer treatment reviews.

[52]  M. Ladanyi,et al.  Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  N. Hanna,et al.  Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  J. Szustakowski,et al.  STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort , 2020, ESMO Open.

[55]  Y. Yatabe,et al.  Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck , 2020, The journal of pathology. Clinical research.

[56]  J. Lunceford,et al.  KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC , 2019 .

[57]  J. Lunceford,et al.  LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 , 2019 .

[58]  M. Eisenhut,et al.  Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis , 2019, Cancers.

[59]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[60]  Z. Lohinai,et al.  KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy , 2019, Cancers.

[61]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[62]  J. Heymach,et al.  Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy , 2019, Nature Reviews Cancer.

[63]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[65]  M. Kris,et al.  Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  V. Papadimitrakopoulou,et al.  Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer , 2019, Clinical Cancer Research.

[67]  M. Hellmich,et al.  K‐ras Mutation Subtypes in NSCLC and Associated Co‐occuring Mutations in Other Oncogenic Pathways , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[68]  Jiamei Li,et al.  Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer , 2019, Oncology letters.

[69]  L. Paz-Ares,et al.  KRAS-Mutant non-small cell lung cancer: From biology to therapy. , 2018, Lung cancer.

[70]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[71]  Paul Baas,et al.  Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[72]  L. Borsu,et al.  Bronchiolar Adenoma: Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases , 2018, The American journal of surgical pathology.

[73]  F. Ghazi,et al.  Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients , 2018, PloS one.

[74]  J. Szustakowski,et al.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. , 2018, Cancer discovery.

[75]  B. Levy,et al.  Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer , 2018, Clinical Cancer Research.

[76]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[77]  C. Paweletz,et al.  False-Positive Plasma Genotyping Due to Clonal Hematopoiesis , 2018, Clinical Cancer Research.

[78]  Brooke L. Billman,et al.  Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Robyn L. Temple-Smolkin,et al.  Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.

[80]  L. Shlush Age-related clonal hematopoiesis. , 2018, Blood.

[81]  S. Mortimer,et al.  The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients , 2017, Clinical Cancer Research.

[82]  M. Ladanyi,et al.  Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.

[83]  Jordi Remon,et al.  LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value. , 2017, Lung cancer.

[84]  Francisco J. Sánchez-Rivera,et al.  Keap1 loss promotes Kras-driven lung cancer and results in a dependence on glutaminolysis , 2017, Nature Medicine.

[85]  Xiaozhen Liu,et al.  Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer , 2017, Oncology Letters.

[86]  F. López-Ríos,et al.  Treating KRAS-mutant NSCLC: latest evidence and clinical consequences , 2017, Therapeutic advances in medical oncology.

[87]  L. Wood,et al.  Cancer‐Associated Mutations in Endometriosis without Cancer , 2017, The New England journal of medicine.

[88]  R. Büttner,et al.  KRAS mutation in papillary fibroelastoma: a true cardiac neoplasm? , 2017, The journal of pathology. Clinical research.

[89]  Jian Su,et al.  Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[90]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[91]  C. Der,et al.  RAS isoforms and mutations in cancer at a glance , 2016, Journal of Cell Science.

[92]  Jing Wang,et al.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. , 2016, Cancer research.

[93]  M. Ladanyi,et al.  Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[94]  B. Das,et al.  Molecular Spectrum of Somatic EGFR and KRAS Gene Mutations in non Small Cell Lung Carcinoma: Determination of Frequency, Distribution Pattern and Identification of Novel Variations in Indian Patients , 2015, Pathology & Oncology Research.

[95]  A. Chella,et al.  PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients , 2014, British Journal of Cancer.

[96]  S. Fesik,et al.  Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.

[97]  J. Neal,et al.  Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung. , 2014, Archives of pathology & laboratory medicine.

[98]  C. Sima,et al.  Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[99]  P. Ellis,et al.  Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. , 2013, Current oncology.

[100]  J. Ahn,et al.  Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer , 2013, PloS one.

[101]  A. Levonen,et al.  The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer☆ , 2013, Redox biology.

[102]  Carla Mattos,et al.  A comprehensive survey of Ras mutations in cancer. , 2012, Cancer research.

[103]  M. Socinski,et al.  Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  L. Seymour,et al.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  Masayuki Yamamoto,et al.  Oxidative Stress Sensor Keap1 Functions as an Adaptor for Cul3-Based E3 Ligase To Regulate Proteasomal Degradation of Nrf2 , 2004, Molecular and Cellular Biology.

[106]  G. Sapkota,et al.  LKB1, a protein kinase regulating cell proliferation and polarity , 2003, FEBS letters.

[107]  T. Schlange,et al.  Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows. , 2019, Clinical chemistry.

[108]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[109]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[110]  M Broggini,et al.  Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.